6,531 followers
New research: Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab: Background Bevacizumab is the representative drug in antiangiogenic therapy for lung cancer. However, it induced resistance in some neoplasm. Anlotinib, a novel… https://t.co/g86Qj